Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SPL23-ASO

            Therapeutic Area: Genetic Disease Product Name: SPL23-ASO

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 11, 2021

            Details:

            Data show that SPL23-ASO, targeting the W1282X nonsense mutation, enables production of a functional cystic fibrosis transmembrane conductance regulator protein.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JAG101

            Therapeutic Area: Genetic Disease Product Name: JAG101

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: $139.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing April 13, 2021

            Details:

            Jaguar will use Series B funding proceeds to continue to advance its initial pre-clinical pipeline, which utilizes the proven and well-characterized AAV9 vector to target diseases in larger patient populations with significant unmet need.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JAG101

            Therapeutic Area: Genetic Disease Product Name: JAG101

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 25, 2021

            Details:

            Jaguar Gene Therapy is focused on advancing its initial pre-clinical pipeline of AAV9-based gene therapies which includes JAG101, JAG201, JAG301, AXV101 focusing on key therapeutic areas such as galactosemia, autism spectrum disorder, Type 1 diabetes and BBS1 respectively.